On November 11, 2024, Brian Ratzan, a Director at The Simply Good Foods Co (SMPL, Financial), executed a sale of 66,483 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 2,099,387 shares of The Simply Good Foods Co.
The Simply Good Foods Co, known for its focus on nutritional foods and snack products, continues to make strides in the health and wellness sector. The company's offerings primarily cater to consumers looking for convenient, nutritious, and tasty food options.
Shares of The Simply Good Foods Co were priced at $36.28 on the day of the transaction. This pricing positions the company with a market cap of approximately $3.68 billion. The price-earnings ratio stands at 26.60, which is above the industry median of 18.31.
According to the GF Value, The Simply Good Foods Co has a current price-to-GF-Value ratio of 0.87, suggesting that the stock is Modestly Undervalued. The GF Value is a proprietary measure used to determine the fair value of a stock, incorporating historical trading multiples, a GuruFocus adjustment factor, and future business performance estimates.
Over the past year, Brian Ratzan has sold a total of 280,768 shares and has not made any purchases. The overall insider transaction trend for The Simply Good Foods Co shows a total of 15 insider sells and no insider buys over the same period.
This insider activity occurs within the context of the company's stock performance and valuation metrics, providing investors with insights into insider confidence and market perceptions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
